Table 2

Procedural aspects and use of AADs

Author (year)Ablation procedureNumber of proceduresUse of AADs after blanking
Liu et al (2005)14PVI1.3
Second procedure: 25% (1)
Oral amiodarone in one patient (25%) to prevent AT relapses after second procedure
Kilicaslan et al (2006)15PVI1.3
Second procedure: 25.9% (7)
5 of 13 patients (38.5%) with relapse after the first procedure remained in SR on AADs
1 out of 2 patients with relapse after the second procedure remained in SR on AADs
Gaita et al (2007)16PVI+roof line+mitral isthmus1.2
Second procedure: 19.2% (5)
10 of 16 patients (62.5%) in SR were off AADs
Bunch et al (2008)17Ostial PVI in 15 patients+roof line and mitral isthmus in seven patients
WACA+roof line and mitral isthmus in 18 patients
Second procedure: 39% (13)
Of the 78% patients in SR at 1 year, 14% were under AADs
Of the 74% patients in SR at 3 years, 27% were under AADs
Di Donna et al (2010)18PVI+roof line+mitral isthmus+CTI (under fluoroscopic guidance in 15 patients)1.5
Second procedure: 52%
11 of 17 patients (64.7%) in SR after the first procedure were on AADs
11 of 24 patients (45.8%) in SR after the second procedure were on AADs
McCready et al (2011)19PVI± roof line, mitral isthmus and CFAE ablation at the discretion of the operatorHCM 1.5; controls 1.3
Second procedure: 71.4% (10) HCM
Third procedure: 14.3% (2) HCM
Fourth procedure: 7.1% (1) HCM
The two patients with HCM in SR after catheter ablation were on AADs
Derejko et al (2013)20Ostial PVI+CTI line ± mitral isthmus, roof line and CFAE ablation at the discretion of the operator1.4
Second procedure: 43% (13)
16 patients with no AF/AT relapse at 12 months were under AADs and these were stopped in five patients
Santangeli et al (2013)21All patients: PVI+posterior wall isolation between PVs+SVC isolation
Persistent AF: +all posterior wall (CS and left side of septum)+CFAE (LA and CS)
Redo: +non-PV triggers
Second procedure: 58% (25)
(All patients with recurrence)
91% of patients in SR at 12 months, but only 76% off ADDs
Yan et al (2013)22PVI± roof line, mitral isthmus or CTI line1.1Eight of nine patients with HCM (88.9%) were free from AF recurrence without AADs
Hayashi et al (2014)23PVI+roof line+posterior inferior line+CTI±mitral isthmus, if persistent AFHCM 1.5; controls 1.4
Second procedure: 47% (8) HCM, 35% (12) controls (p=0.87)
AADs used more frequently in patients with HCM (47% vs 12%, p=0.008)
Contreras-Valdes et al (2015)24PVI
Ablation of sustained organised AT
HCM 1.3±0.5
Controls 1.2±0.4 (p=0.7)
Chronic AADs in 45% HCM vs 18.8% controls (p=0.007)
Müssigbrodt et al (2015)25PVI±roof line, septal line and CTI lineHCM 1.4, controls 1.1
Second procedure: five patients with HCM vs three controls
Third procedure: three patients with HCM (p=0.045)
6 of 22 (27%) patients with HCM treated with AADs vs none in non-HCM group (p=0.008)
Okamatsu et al (2015)26PVI±CTI1.1
Second procedure: three patients with HCM
15 (68%) patients used concomitant AADs
Wen et al (2015)27Paroxysmal AF: PVI+CTI (if documentation of typical flutter).
Persistent AF: +roof line, mitral isthmus and CTI
  • AADs, antiarrhythmic drugs; AF, atrial fibrillation; AT, atrial tachycardia; CFAE, complex fractionated atrial electrograms; CS, coronary sinus; CTI, cavotricuspid isthmus; HCM, hypertrophic cardiomyopathy; LA, left atrium; N.A., not available; PVI, to be interpreted as wide antral circumferential ablation, unless stated ostial PVI; PV, pulmonary vein; SVC, superior vena cava; SR, sinus rhythm; WACA, wide antral circumferential ablation.